Marina Cerqua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marina Cerqua has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Dogus Murat Altintas
IFOM
2 shared publications - Carla Boccaccio
Laboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
1 shared publication - Cédric Chaveroux
Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS 5286, Centre Léon Bérard Université de Lyon, Université Claude Bernard Lyon 1 France
1 shared publication - Estelle Bigot1 shared publication
Marco Foiani
IFOM ETS-The AIRC Institute of Molecular Oncology, 20139, Milano, Italy
1 shared publicationPaolo M. Comoglio
1 shared publication
Latest Publications
- Open Access
- 13 October 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (10)
Untranslated region rewiring defines a novel class of oncogene fusions
- 13 October 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (10)
Open AccessUntranslated region rewiring defines a novel class of oncogene fusions
- Open Access
- 7 January 2025
- Published by Springer Nature in The EMBO Journal
- Vol. 44 (4) , 1107-1130
The integrated stress response drives MET oncogene overexpression in cancers
Cancer cells rely on invasive growth to survive in a hostile microenvironment; this growth is characterised by interconnected processes such as epithelial-to-mesenchymal transition and migration. A master regulator of these events is the MET oncogene, which is overexpressed in the majority of cancers; however, since mutations in the MET oncogene are seen only rarely in cancers and are relatively infrequent, the mechanisms that cause this widespread MET overexpression remain obscure. Here, we show that the 5’ untranslated region (5’UTR) of MET mRNA harbours two functional stress-responsive elements, conferring translational regulation by the integrated stress response (ISR), regulated by phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2 α ) at serine 52. ISR activation by serum starvation, leucine deprivation, hypoxia, irradiation, thapsigargin or gemcitabine is followed by MET protein overexpression. We mechanistically link MET translation to the ISR by (i) mutation of the two uORFs within the MET 5’UTR, (ii) CRISPR/Cas9-mediated mutation of eIF2 α (S52A), or (iii) the application of ISR pathway inhibitors. All of these interventions reduce stress-induced MET overexpression. Finally, we show that blocking stress-induced MET translation blunts MET-dependent invasive growth. These findings indicate that upregulation of the MET oncogene is a functional requirement linking integrated stress response to cancer progression.
- 7 January 2025
- Published by Springer Nature in The EMBO Journal
- Vol. 44 (4) , 1107-1130
Open AccessThe integrated stress response drives MET oncogene overexpression in cancers
Cancer cells rely on invasive growth to survive in a hostile microenvironment; this growth is characterised by interconnected processes such as epithelial-to-mesenchymal transition and migration. A master regulator of these events is the MET oncogene, which is overexpressed in the majority of cancers; however, since mutations in the MET oncogene are seen only rarely in cancers and are relatively infrequent, the mechanisms that cause this widespread MET overexpression remain obscure. Here, we show that the 5’ untranslated region (5’UTR) of MET mRNA harbours two functional stress-responsive elements, conferring translational regulation by the integrated stress response (ISR), regulated by phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2 α ) at serine 52. ISR activation by serum starvation, leucine deprivation, hypoxia, irradiation, thapsigargin or gemcitabine is followed by MET protein overexpression. We mechanistically link MET translation to the ISR by (i) mutation of the two uORFs within the MET 5’UTR, (ii) CRISPR/Cas9-mediated mutation of eIF2 α (S52A), or (iii) the application of ISR pathway inhibitors. All of these interventions reduce stress-induced MET overexpression. Finally, we show that blocking stress-induced MET translation blunts MET-dependent invasive growth. These findings indicate that upregulation of the MET oncogene is a functional requirement linking integrated stress response to cancer progression.